Management Team

Gerri Henwood

President & Chief Executive Officer

Gerri Henwood has served as our President and Chief Executive Officer and a director of the Company since our inception in 2008. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Ms. Henwood continues to spend a very small portion of her time engaged in the provision of consulting services for MCG to other companies, including companies that are engaged in the development and commercialization of other pharmaceutical products. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc, in the pharmaceutical management program. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division. Ms. Henwood currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, a position she has held since May 2015, and two private companies, and she previously served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015. Ms. Henwood also serves on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc. Ms. Henwood holds a B.S. in Biology from Neumann University. As our founder and having served as a director since our inception, Ms. Henwood’s extensive knowledge of our business and history, experience as a board member of multiple publicly-traded and privately-held companies, and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies, as well as Ms. Henwood’s strong background in clinical and product development and substantial knowledge of the pharmaceutical industry, contributed to our Board’s conclusion that she should serve as a director of our company.

Michael Celano

Chief Operating Officer

Mr. Celano has over 35 years of senior financial leadership experience in the life sciences and biopharmaceutical industries. Mr. Celano joined Recro in July 2016 as Chief Financial Officer. During his tenure, he has provided financial leadership through several Phase III clinical trials, the filing of the New Drug Application (NDA) for IV meloxicam 30mg and preparing for commercial launch, as well as through the continued strong performance of the Company's manufacturing division. In his new role as Chief Operating Officer, Mr. Celano will continue to lead finance and administration for Recro, and he will assume responsibility for the Company's CDMO division. Prior to joining Recro, Mr. Celano served as Chief Financial Officer at Kensey Nash, a Nasdaq-listed, medical device company, and BioRexis, a venture-funded, life sciences company. Mr. Celano serves on the board of Orasure Technologies (Nasdaq:OSUR). Prior to entering the biopharmaceutical industry, Mr. Celano was a Partner at Arthur Andersen/KPMG, where he worked from 1980 until 2004, and led its life sciences practices. Mr. Celano received a bachelor's degree in accounting from St. Joseph's University.

Ryan D. Lake

Chief Financial Officer

Mr. Lake has served as our Chief Financial Officer since January 2018 and he has over 15 years of senior financial leadership experience. Mr. Lake joined Recro in June 2017 as the Company's Chief Accounting Officer and Senior Vice President of Finance. Prior to joining Recro, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privately-held, commercial-stage, medical device company. From 2012 to 2015, Mr. Lake held executive management and senior finance positions, including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical (successor to Kensey Nash after its acquisition in 2012), a division of Royal DSM (listed on Euronext Amsterdam), a global science-based company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake held various senior financial positions of increasing responsibility, most notably Senior Director of Finance and Interim CFO, with Kensey Nash Corporation, a Nasdaq-listed, medical device company. Earlier in his career, Mr. Lake worked at Deloitte & Touche, LLP. Mr. Lake is a Certified Public Accountant, Chartered Global Management Accountant and holds a B.S. degree in Accounting from West Chester University of Pennsylvania.

Stewart McCallum, MD

Chief Medical Officer

Stewart McCallum, M.D. has served as our Chief Medical Officer since December 2015. From 2006 to 2015, Dr. McCallum worked at GlaxoSmithKline plc (GSK), a research-based pharmaceutical and healthcare company. While at GSK he served in a range of roles in discovery and development and ultimately as Clinical Director of the Academic and Sirtuin, Discovery Performance Units. During his time at GSK, Dr. McCallum successfully led high profile drug development programs across a wide variety of therapeutic areas including urology, oncology, gastroenterology, dermatology, stem cell therapies, in vitro fertilization and women’s health. While at GSK he was responsible for the planning, design and execution of comprehensive development plans incorporating medical, regulatory and commercial considerations. From 1998 to 2006, Dr. McCallum served as an Assistant Professor of Urology at Stanford University Medical Center and the VA Palo Alto Health Care System. Dr. McCallum received his M.D. from the University of Toronto and his B.S. in Biochemistry from the University of Western Ontario. He completed his residency in Urology at the University of Toronto and a Clinical Fellowship in Microsurgery and Male Infertility at the Weill Cornell Medical College at New York–Presbyterian Hospital.  Dr. McCallum is a Certified Diplomat of the American Board of Urology; Fellow of the American College of Surgeons, and Fellow of the Royal College of Surgeons Canada.

John Harlow

Executive Vice President, Commercial

John Harlow has served as our Executive Vice President, Commercial since February 2018 and has over 20 years of branded pharmaceutical experience, including commercial leadership roles in marketing, sales and operations. He joined Recro as our Vice President of Marketing in October 2016. From 2015 to 2016, Mr. Harlow served as the Vice President & General Manager of the Pain Business Unit for Endo Pharmaceuticals. Prior to Endo, Mr. Harlow spent over 3 years at Shionogi in roles of increasing responsibilities including Vice President, Sales and Marketing and Vice President of Sales, Training and Operations. Prior to joining Shionogi, Mr. Harlow was a Senior Director of Marketing at King Pharmaceuticals where he oversaw the pain portfolio that was ultimately acquired by Pfizer. Mr. Harlow spent over 6 years with Novartis Pharmaceuticals in sales management and marketing leadership roles in the Neuroscience business unit. Earlier in his career, Mr. Harlow was an equity research analyst at Merrill Lynch and a sales representative at Janssen Pharmaceuticals - a Johnson and Johnson company. He earned a BS in Biology from Lehigh University and an M.B.A. in Pharmaceutical Management & Marketing from The Stillman School of Business at Seton Hall University.

Randy Mack

Senior Vice President, Development

Randall Mack has served as our Senior Vice President, Development and Secretary since 2008. From 2008 to 2014, Mr. Mack served as Executive Vice President, Development for MCG, a pharmaceutical incubator and consulting firm. Mr. Mack continues to spend a small portion of his time engaged in the provision of consulting services for MCG to other companies, including companies that are engaged in the development and commercialization of other pharmaceutical products. From 2005 to 2008, Mr. Mack served as Vice President, Project Management and Operations at Adolor Corporation where he oversaw the development programs in the areas of opioid-induced bowel dysfunction and pain management. For more than 15 years, he also held positions of increasing responsibilities at Auxilium, Abbott Laboratories and Harris Laboratories. In these positions he was responsible for the conduct of over 400 clinical trials and the filing of 20 INDs and 4 NDAs. During his career he has authored more than 75 scientific articles, book chapters, abstracts and poster presentations in the areas of gastroenterology, urology, neuroscience and psychiatric disorders. Mr. Mack holds a B.S. in Biology and Chemistry from the University of Nebraska-Lincoln.

Diane Myers

Senior Vice President, Regulatory Affairs & Quality Assurance

Diane Myers has served as our Senior Vice President, Regulatory and Quality since 2008. From 2008 to 2014, Ms. Myers served as Senior Vice President of Regulatory Affairs and Quality Assurance for MCG, a pharmaceutical incubator and consulting firm. Ms. Myers continues to spend a small portion of her time engaged in the provision of consulting services for MCG to other companies, including companies that are engaged in the development and commercialization of other pharmaceutical products. From 2000 to 2008, Ms. Myers served as Vice President of Regulatory Affairs and Quality at Auxilium. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline plc in the Quality Control and Quality Assurance groups within the Biopharmaceutical Research and Development Division. Ms. Myers holds a B.S. in Biology from Neumann University. Ms. Myers is Ms. Henwood’s sister.

Jyrki Mattila, M.D., Ph.D.

Executive Vice President of Business Development

Dr. Mattila joins Recro Pharma from Lipocine Inc., a specialty pharmaceutical company, where he served for two years as Chief Business Officer.  From 2010 to 2015, Dr. Mattila held executive management positions, serving as Chief Business Officer at iCeutica Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc.  From 2003 to 2010, Dr. Mattila served as Executive Vice President, Business Development, Product Development and Technical Operations, at Auxilium Pharmaceuticals Inc., where he contributed to Auxilium’s growth from a private start-up to a publicly-traded specialty pharmaceutical company.  From 1986 to 2003, Dr. Mattila held positions of increasing responsibility at Orion Corporation in business development, R&D and executive general management.  Dr. Mattila served as a Post-Doctoral Research Fellow at the University of Kansas Medical Center and holds a M.B.A. from the Helsinki School of Economics, a Ph.D. from the Department of Pharmacology at the University of Helsinki and a M.D. from the University of Helsinki Medical School.